冯德莱恩和特朗普在两大关键问题上表述矛盾，落实仍有变数

Group 1 - The US and EU have reached a new trade agreement, reducing tariffs on most EU imports to 15%, down from a threatened 30% [1] - The agreement does not cover pharmaceuticals, with conflicting statements from US President Trump and EU Commission President von der Leyen regarding the inclusion of drug tariffs [1][4] - The US is initiating a "232 investigation" to assess whether imports of specific products, including pharmaceuticals, pose a national security threat [1][2] Group 2 - Disagreements remain regarding steel and aluminum tariffs, with Trump stating that a 50% tariff will remain unchanged, while von der Leyen suggests a reduction and quota system [4] - Key areas such as chips and spirits still lack a definitive tariff agreement, indicating ongoing negotiations [4] - The trade agreement has faced criticism within Europe, with concerns about its fairness and potential long-term harm to the EU [5]